Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus docetaxel for taxane-pretreated HER2-negative metastatic breast cancer
ChiCTR-OIC-16009581Phase 2Recruiting
- Sponsor
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Start
- Oct 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and docetaxel in breast cancer, sponsored by Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Primary endpoint: Objective response rate. Started Oct 2016; status: recruiting.
02
Drugs
Rivoceranibdocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-OIC-16009581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16009581.